Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Lim ABM, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori RU, Farooqui MZH, Marinello P, San-Miguel J; KEYNOTE-185 Investigators. Usmani SZ, et al. Among authors: kosugi h. Lancet Haematol. 2019 Sep;6(9):e448-e458. doi: 10.1016/S2352-3026(19)30109-7. Epub 2019 Jul 18. Lancet Haematol. 2019. PMID: 31327689 Clinical Trial.
Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients.
Takezako N, Kosugi H, Matsumoto M, Iida S, Ishikawa T, Kondo Y, Ando K, Miki H, Matsumura I, Sunami K, Teshima T, Iwasaki H, Onishi Y, Kizaki M, Izutsu K, Maruyama D, Tobinai K, Ghori R, Farooqui M, Liao J, Marinello P, Matsuda K, Koh Y, Shimamoto T, Suzuki K. Takezako N, et al. Among authors: kosugi h. Int J Hematol. 2020 Nov;112(5):640-649. doi: 10.1007/s12185-020-02953-3. Epub 2020 Sep 19. Int J Hematol. 2020. PMID: 32949374
Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients.
Matsumoto M, Suzuki K, Kuroda J, Taniwaki M, Sunami K, Kosugi H, Ando K, Maruyama D, Tobinai K, Kher U, Farooqui M, Liao J, Marinello P, Matsuda K, Koh Y, Shimamoto T, Iida S. Matsumoto M, et al. Among authors: kosugi h. Int J Hematol. 2021 Jun;113(6):777-784. doi: 10.1007/s12185-021-03139-1. Epub 2021 Apr 15. Int J Hematol. 2021. PMID: 33856638 Clinical Trial.
Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.
Suzuki K, Dimopoulos MA, Takezako N, Okamoto S, Shinagawa A, Matsumoto M, Kosugi H, Yoon SS, Huang SY, Qin X, Qi M, Iida S. Suzuki K, et al. Among authors: kosugi h. Blood Cancer J. 2018 May 1;8(4):41. doi: 10.1038/s41408-018-0071-x. Blood Cancer J. 2018. PMID: 29712896 Free PMC article. Clinical Trial.
Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR.
Takezako N, Shibayama H, Handa H, Hagiwara S, Ozaki S, Suzuki K, Kosugi H, Ri M, Sugiura I, Choi I, Miyamoto T, Iida S. Takezako N, et al. Among authors: kosugi h. Int J Hematol. 2021 Feb;113(2):219-230. doi: 10.1007/s12185-020-03013-6. Epub 2020 Oct 10. Int J Hematol. 2021. PMID: 33037990 Free PMC article.
Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation.
Suzuki K, Doki N, Meguro K, Sunami K, Kosugi H, Sasaki O, Takagi T, Murakami H, Shimizu K. Suzuki K, et al. Among authors: kosugi h. Int J Hematol. 2019 Oct;110(4):447-457. doi: 10.1007/s12185-019-02700-3. Epub 2019 Jul 19. Int J Hematol. 2019. PMID: 31325152 Clinical Trial.
Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma.
Ishida T, Kimura H, Ozaki S, Kubo K, Sunami K, Takezako N, Fujita H, Hayashi T, Kiguchi T, Ohashi K, Yamamoto S, Takamatsu H, Kosugi H, Ohta K, Sakai R, Handa H, Kondo S, Abe Y, Omoto E, Mitani K, Morita S, Murakami H, Shimizu K. Ishida T, et al. Among authors: kosugi h. Ann Hematol. 2020 May;99(5):1063-1072. doi: 10.1007/s00277-020-03988-6. Epub 2020 Apr 4. Ann Hematol. 2020. PMID: 32248251 Clinical Trial.
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network.
Soekojo CY, Kim K, Huang SY, Chim CS, Takezako N, Asaoku H, Kimura H, Kosugi H, Sakamoto J, Gopalakrishnan SK, Nagarajan C, Wei Y, Moorakonda R, Lee SL, Lee JJ, Yoon SS, Kim JS, Min CK, Lee JH, Durie B, Chng WJ. Soekojo CY, et al. Among authors: kosugi h. Blood Cancer J. 2019 Oct 8;9(10):83. doi: 10.1038/s41408-019-0245-1. Blood Cancer J. 2019. PMID: 31594919 Free PMC article. Clinical Trial.
108 results